Lv31
290 积分 2023-04-28 加入
Alternative routes of drug administration: exposure of imatinib using different formulations
3小时前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
1个月前
已完结
Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays
1个月前
已完结
Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1‐Positive NSCLC or NTRK‐Positive Solid Tumors
1个月前
已完结
Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights
2个月前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
2个月前
已完结
Mechanisms of osimertinib resistance and emerging treatment options
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
3个月前
已完结
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
3个月前
已完结
皖公网安备34019202002308
